Kura Oncology Reported Preclinical Data Supporting The Development Of The Company's Menin Inhibitor, Ziftomenib, For Advanced Gastrointestinal Stromal Tumors
Portfolio Pulse from Benzinga Newsdesk
Kura Oncology has reported promising preclinical data for its menin inhibitor, ziftomenib, in combination with imatinib for treating advanced gastrointestinal stromal tumors (GIST). The combination showed superior antitumor activity compared to imatinib alone. The FDA has cleared the IND application for ziftomenib, and Kura plans to start a proof-of-concept study in 2025.
October 24, 2024 | 11:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kura Oncology's preclinical data shows that ziftomenib, in combination with imatinib, is effective against advanced GIST. The FDA has cleared the IND application, and a study is planned for 2025.
The preclinical data suggests a significant advancement in treatment for GIST, potentially enhancing Kura's product pipeline. FDA clearance of the IND application is a positive regulatory milestone, likely boosting investor confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100